Chat with us, powered by LiveChat

Loading...

Connected Drug Delivery Devices Market Report

RA00348

Connected Drug Delivery Devices Market, by Type (Injectable Devices, Inhalation Devices, and Others), by Technology (NFC, Bluetooth, Others), by End-User (Homecare settings and Hospitals) Regional Analysis (North America, Europe, Asia Pacific, LAMEA): Global Opportunity Analysis and Industry Forecast, 2020–2027

RA00348

Pages: 180

Aug 2020

COVID-19

pandemic has shown to have an enormous impact on most
industries.

Click Here to access our comprehensive analysis of the

Impact of covid-19 on Connected Drug Delivery Devices Market

The global connected drug delivery devices market forecast will be $1,119.3 million by 2027, increasing from $184.9 million in 2019 at a healthy CAGR of 24.6%. Asia-Pacific connected drug delivery devices market is expected to grow at a healthy CAGR of 26.3% by generating a revenue of $190.3 million, during the forecasted period. The technological innovations along with strategic collaborations are anticipated to augment the growth of the market in the Asia-Pacific region.

Connected Drug Delivery Devices Market Analysis:

The connected drug delivery products help in addressing patient’s issues associated with disease management protocols, treatments, and medications. Connected drug delivery is one of the emerging solutions equipped with a sensor that facilitates connection and transfer of data to servers/applications via near field communication (NFC), Bluetooth, or cellular networks.

Impact Analysis of COVID-19 on Connected Drug Delivery Devices Market:

The unprecedented situation of the coronavirus disease (COVID-19) across the globe has led to a shutdown of industries for an uncertain time period. The processes of businesses such as production, inventory management, and distribution of goods & services have stopped owing to this shutdown, which is predicted to create a dramatic impact on the global marketplace. Contrary to this, the pandemic spread of COVID-19 may create a positive impact on the global connected drug delivery devices market. Several global leaders involved in the connected drug delivery devices market are coming forward with strategic steps to serve their products and services to society, during the COVID-19 pandemic. For instance, in January 2020, Aptar Pharma, a pioneer in drug delivery systems, partnered with Lupin to Launch ADHERO, India’s 1st connected drug delivery device for the COPD (chronic obstructive pulmonary disease) and asthma suffering patients. The device is Bluetooth enabled and improves the adherence to prescribed therapy along with track MDI (Metered-dose inhaler) usage of patients with chronic respiratory diseases. In addition to this, in February 2020, BD (Becton, Dickinson and Company), a significant global medical technology company, made an announcement of the completion of a 50-subject human clinical trial by using ‘BD Libertas Wearable Injector’. These initiatives and technological up-gradation may lead to creating lucrative market opportunities for the global connected drug delivery devices market. By implementation of such effective strategies, ventures around the world are gaining the trust of people and preparing for the post-pandemic impact.

The increasing prevalence of chronic diseases is expected to flourish the global connected drug delivery devices market, during the analysis period.

The extensively growing demand for connected drug delivery technologies is mainly attributed to the increase in the cases of chronic disorders such as diabetes, asthma, and COPD. For instance, as per the study conducted by researchers at Tongji Medical College and Huazhong University of Science and Technology, China states that the deaths cases of chronic lung diseases increased by up to 18%, from 3.3 million in 1990 to 3.9 million in 2017 worldwide. These figures showcase that the need for connected drug delivery solution is predicted to increase in the coming years. Contrary to this, several companies operating in connected drug delivery technologies are implementing effective strategies to gain a prime position in the global industry. For instance, in November 2019, LOG pharma, a notable player in the healthcare industries, has announced to release IoT-enabled ‘ActiveGuard’ connect a smart device. This innovative device is primarily developed to address the problem of lack of patient adherence to prescribed medications. These technological developments and upgradations may lead to accelerating the growth of the global connected drug delivery devices market, in the forecast years.

To know more about connected drug delivery devices market drivers, get in touch with our analysts here.

https://www.researchdive.com/connect-to-analyst/348

High costs of connected drug delivery technologies along with lower product penetration projected to obstruct the growth of the global market

Though connected drug delivery technologies provide improved patient outcomes, the current global market is obstructed mainly owing to the higher costs of advanced devices. In addition, inadequate reimbursement policies, lack of awareness among patient about the latest technologies, and low product penetration in the middle and low-income countries are expected to decrease the demand for connected during delivery devices, which will ultimately create a negative impact on the global market, during the analysis period.

A growing emphasis on novel technologies in connected drug delivery solutions to create huge investment opportunities

The increasing promise of connected drug delivery devices is highlighted by many emerging as well as established organizations. Furthermore, the significantly growing adoption of cutting-edge technologies in the connected drug delivery devices is projected to generate noteworthy revenue in the review period. Key players operating in the healthcare sector are adopting such technologies to develop highly efficient along with low-cost connected drug delivery solutions. For instance, in February 2019, Phillips-Medisize has announced to exhibit and promote its recent innovation in connected drug delivery devices at Pharmapack’s Innovation Gallery. These devices provide better performance over other connected drug delivery solutions coupled with they are cost-effective. Also, in October 2018, the company has made an announcement that they have launched a ‘cloud-based data system’ particularly for the drug delivery device developers. These aforementioned factors are expected to generate lucrative market opportunities for the connected drug delivery devices market growth, in the upcoming decades.  

To know more about Connected drug delivery devices Market Opportunities, get in touch with our analysts here.

https://www.researchdive.com/connect-to-analyst/348

Connected Drug Delivery Devices Market, by Type:

The injectable devices will generate a revenue of $652.2 million by 2027, mainly because of rising cases of cancer and diabetes patients

The injectable devices will generate a revenue of $652.2 million by 2027, mainly because of rising cases of cancer and diabetes patients

Technology: Research Dive Analysis

Injectable devices have the highest market share and they are expected to register a revenue of $652.2 million by 2027, growing from $113.1 million in 2019. Injectable drug delivery is identified as the most efficient route of administration due to the effectiveness of drug delivery to the target. Furthermore, the massively growing usage of electronic technology in the healthcare equipment is predicted to accelerate the global connected injectable devices market growth, during the forecast years. On the other hand, the inhalation devices will have exponential market growth and are estimated to reach up to $467.1 million, in the review period due to the rising prevalence of chronic respiratory illnesses such as COPD and asthma.

Connected Drug Delivery Devices Market, by Technology:

The Bluetooth sub-segment will have a significant market share in the global market; this is mainly because of cost-effective connectivity access to smartphones

The Bluetooth sub-segment will have a significant market share in the global market; this is mainly because of cost-effective connectivity access to smartphones

Technology: Research Dive Analysis

Connected drug delivery devices market for Bluetooth technology shall have substantial growth and it is expected to account for $733.0 million by 2027, with an increase from $122.8 million in 2019. Bluetooth based drug delivery device is one of the leading preference in medicine delivery mainly due to its widespread availability of low-cost connectivity access to smartphones. Moreover, ventures operating in the global market are developing novel products and technology to stronghold the position in the global industry. For instance, in July 2020, Teva, a pioneer in improving health and increasing access to quality healthcare for society has released a Bluetooth-enabled albuterol sulfate rescue inhaler. The highly advanced ‘ProAir Digihaler’ connects with the smartphone to manage COPD and asthma symptoms. These factors may help in the blooming the global connected drug delivery devices market, throughout the projected timeframe.

However, the connected drug delivery devices market for the NFC devices has the fastest growth in the global market and is further projected to register a revenue of $290.3 million, by 2027. NFC technology plays a major role in drug delivery for the enhancement of patient outcomes. extended battery life, Superior data transmission, and excellent accuracy are the features accelerating the demand for NFC devices, which will ultimately foster the sub-segment growth, during the analysis timeframe. In addition to this, the presence of significant companies like Adherium, Ypsomed, and Aptar Group and their heavy investment in the research and innovations may also lead to fuel the growth of the sub-segment, in the projected timeframe.

Connected Drug Delivery Devices Market, by End-user:

The hospital sub-segment shall have a dominating market share in the global market; this is mainly because of cost-effective connectivity access to smartphones

The hospital sub-segment shall have a dominating market share in the global market; this is mainly because of cost-effective connectivity access to smartphones

Technology: Research Dive Analysis

The hospital sub-segment shall have a lucrative market share and is anticipated to register a revenue of $805.8 million by 2027, rising from $141.6 million in 2019. Healthcare costs have increased in the last few years. Also, the hospitals have become astonishingly digitalized with the implementation of electronic and connectivity technologies. Moreover, the growing adoption of connected drug delivery solutions in hospitals, smartphones to support healthcare professionals, and integrated diagnostic technology for improved disease detection are anticipated to generate the noteworthy revenue of the sub-segment, during the forecast period.

However, the homecare settings sub-segment shall have rapid market growth and is projected to generate a revenue of $313.5 million by 2027, surging from $47.8 million in 2019 owing to the technology boom in healthcare settings such as integration of AI and IoT. In addition to this, a growing geriatric population, increasing prevalence of chronic respiratory diseases are also further predicted to offers market opportunities for the sub-segment, throughout the review period.

Regional Insights:

Asia-Pacific region has a lucrative market and it will reach up to $190.3 million by the end of 2027 increasing from 28.8 million in 2019

Asia-Pacific region has a lucrative market and it will reach up to $190.3 million by the end of 2027 increasing from 28.8 million in 2019

Technology: Research Dive Analysis

The Asia-Pacific connected drug delivery devices’ market shall have a lucrative market opportunities and is estimated to generate a revenue of $190.3 million by 2027, surging from $28.8 million in 2019.

Rising prevalence of chronic disorders, technological advances, and cutting-edge connected drug delivery products are some of the driving factors that are expected to foster the demand for connected drug delivery devices in the European market. In addition, companies are emphasizing more on strategic collaborations to develop integrated products and to grow in the global market. For example, in April 2020, Sonmol, a significant Chinese digital respiratory therapeutics organization, has announced the collaboration with the Aptar group for developing digital therapies for the treatment of respiratory and other disorders. The joint venture shall initially concentrate on the digital platform and connected drug delivery devices for asthma and COPD diseases. These alliances may lead to a surge in the connected drug delivery devices market growth in the Asian countries, during the projected period.

The connected drug delivery devices market size in North America generated a revenue of $78.9 million in 2019 and it is projected to account for $436.5 million by 2027. Leading players of the U.S. are investing heavily in R&D and showcasing the newest technology innovations. For example, in January 2018, Aptar Group, a pioneer in drug delivery systems provider, has announced to exhibit at Pharmapack 2018. In this event, the organization announced to exhibit significant connected healthcare solutions, that can greatly improve patient outcomes and adherence. Such initiatives are further predicted to create investment opportunities for the connected drug delivery devices market, in the North America region. Furthermore, established as well as as star-up companies are looking forward to collaboration with other ventures for the development of innovative connected drug delivery technologies. These factors may lead to generate significant revenue

Competitive Scenario in the Global Connected Drug Delivery Devices Market:

Mergers & acquisitions, along with advanced product development are the frequent strategies followed by the leading market players

Mergers & acquisitions, along with advanced product development are the frequent strategies followed by the leading market players

Technology: Research Dive Analysis

Some of the significant connected drug delivery devices market players include Adherium, BD, Proteus Digital Health, propeller Health, F. Hoffmann-La Roche Ltd, Ypsomed AG, Cohero Health, Inc., West Pharmaceutical Services, Syncro Technology Corp., and AptarGroup Inc.

Connected drug delivery devices market players are focusing on successful product development and their launching, Merger & acquisition, and capacity expansions. These are the most frequent strategies followed by the established as well as emerging ventures.

Porter’s Five Forces Analysis for Connected Drug Delivery Devices Market:

  • Bargaining Power of Suppliers: The number of suppliers involved in the global connected drug delivery devices market is high. Therefore, the switching cost from one supplier to the other supplier is expected to be Low.

          The bargaining power of suppliers is MODERATE.

  • Bargaining Power of Buyer: The product dependency of the connected drug delivery devices is increasing at a constant speed. Also, the number of connected drug delivery device buyers is high.

Thus, the bargaining power of the buyer is MODERATE

  • The Threat of New Entrants: The higher cost associated with research and innovation and a high price war among the established companies may offer a low threat of entry from new competitors.

The threat of new entrants is LOW.

  • The Threat of Substitutes: There is no alternative product available for the connected drug delivery devices.   

Thus, the threat of substitutes is LOW.

  • Competitive Rivalry in the Market: Significant companies operating in the global connected drug delivery devices market are primarily implementing effective strategies such as product introduction, technological innovations, and strategic collaborations to strengthen footprint worldwide.

           Thus, the Competitive Rivalry in the Market is HIGH.  

Aspect

Particulars

Historical Market Estimations

  2019-2020

Base Year for Market Estimation

  2019

Forecast timeline for Market Projection

  2020-2027

Geographical Scope

  North America, Europe, Asia-Pacific, LAMEA

Segmentation by Type

  • Inhalation Devices
  • Injectable Devices
  • Others

Segmentation by Technology

  • Bluetooth
  • NFC
  • Others

Segmentation by End-User

  • Hospitals
  • Homecare Settings

Key Countries Covered

U.S., Canada, Mexico, Germany, France, UK, Italy, Spain, Russia, Rest of Europe, China, Japan, India, Australia, South Korea, Rest of Asia-Pacific, Brazil, Saudi Arabia, United Arab Emirates, Rest of LAMEA

Top 10 Companies Profiled

  • Adherium
  • BD

  • Proteus Digital Health

  • propeller Health

  • F. Hoffmann-La Roche Ltd

  • Ypsomed AG

  • Cohero Health, Inc.

  • West Pharmaceutical Services

  • Syncro Technology Corp.

  • AptarGroup Inc.

 


Frequently Asked Questions
 

A. BD, Ypsomed AG, and Merck KGaA are the leading companies in the connected drug delivery devices market.

A. The Asia-Pacific region possesses great investment opportunities for investors to witness the most promising growth in the future.

A. Technological advancements, product development, along with joint ventures, are the key strategies opted by the operating companies in this market.

A. Adherium and Propeller Health are investing more in R&D practices.

A. Technological advancements, product development, along with joint ventures are the key strategies opted by the operating companies in this market.

A. BD. And Adherium companies are investing more in R&D activities for developing new products and technologies.

1. Research Methodology

1.1. Desk Research
1.2. Real time insights and validation
1.3. Forecast model
1.4. Assumptions and forecast parameters

1.4.1. Assumptions
1.4.2. Forecast parameters

1.5. Data sources

1.5.1. Primary
1.5.2. Secondary

2. Executive Summary

2.1. 360° summary
2.2. Type trends
2.3. Technology trends
2.4. End-User trends

3. Market Overview

3.1. Market segmentation & definitions
3.2. Key takeaways

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. Porter’s five forces analysis

3.3.1. Bargaining power of consumers
3.3.2. Bargaining power of suppliers
3.3.3. Threat of new entrants
3.3.4. Threat of substitutes
3.3.5. Competitive rivalry in the market

3.4. Market dynamics

3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities

3.5. Technology landscape
3.6. Regulatory landscape
3.7. Patent landscape
3.8. Pricing overview

3.8.1. By Type
3.8.2. By Technology
3.8.3. By End-User

3.9. Market value chain analysis

3.9.1. Stress point analysis
3.9.2. Raw material analysis
3.9.3. Manufacturing process
3.9.4. Distribution channel analysis
3.9.5. Operating vendors

3.9.5.1. Raw material suppliers
3.9.5.2. Product manufacturers
3.9.5.3. Product distributors

3.10. Strategic overview

4. Connected Drug Delivery Devices Market, by Type

4.1. Injectable Devices

4.1.1. Market size and forecast, by region, 2020-2027
4.1.2. Comparative market share analysis, 2020 & 2027

4.2. Inhalation Devices

4.2.1. Market size and forecast, by region, 2020-2027
4.2.2. Comparative market share analysis, 2020 & 2027

4.3. Others

4.3.1. Market size and forecast, by region, 2020-2027
4.3.2. Comparative market share analysis, 2020 & 2027

5. Connected Drug Delivery Devices Market, by Technology

5.1. NFC

5.1.1. Market size and forecast, by region, 2020-2027
5.1.2. Comparative market share analysis, 2020 & 2027

5.2. Bluetooth

5.2.1. Market size and forecast, by region, 2020-2027
5.2.2. Comparative market share analysis, 2020 & 2027

5.3. Others

5.3.1. Market size and forecast, by region, 2020-2027
5.3.2. Comparative market share analysis, 2020 & 2027

5.4. Connected drug delivery devices Market, by End-User
5.5. Hospital

5.5.1. Market size and forecast, by region, 2020-2027
5.5.2. Comparative market share analysis, 2020 & 2027

5.6. Homecare Settings

5.6.1. Market size and forecast, by region, 2020-2027
5.6.2. Comparative market share analysis, 2020 & 2027

6. Connected Drug Delivery Devices Market, by Region

6.1. North America

6.1.1. Market size and forecast, by type, 2020-2027
6.1.2. Market size and forecast, by technology, 2020-2027
6.1.3. Market size and forecast, by end-user, 2020-2027
6.1.4. Market size and forecast, by country, 2020-2027
6.1.5. Comparative market share analysis, 2020 & 2027
6.1.6. U.S.

6.1.6.1. Market size and forecast, by type, 2020-2027
6.1.6.2. Market size and forecast, by technology, 2020-2027
6.1.6.3. Market size and forecast, by end-user, 2020-2027
6.1.6.4. Comparative market share analysis, 2020 & 2027

6.1.7. Canada

6.1.7.1. Market size and forecast, by type, 2020-2027
6.1.7.2. Market size and forecast, by technology, 2020-2027
6.1.7.3. Market size and forecast, by end-user, 2020-2027
6.1.7.4. Comparative market share analysis, 2020 & 2027

6.1.8. Mexico

6.1.8.1. Market size and forecast, by type, 2020-2027
6.1.8.2. Market size and forecast, by technology, 2020-2027
6.1.8.3. Market size and forecast, by end-user, 2020-2027
6.1.8.4. Comparative market share analysis, 2020 & 2027

6.2. Europe

6.2.1. Market size and forecast, by type, 2020-2027
6.2.2. Market size and forecast, by technology, 2020-2027
6.2.3. Market size and forecast, by end-user, 2020-2027
6.2.4. Market size and forecast, by country, 2020-2027
6.2.5. Comparative market share analysis, 2020 & 2027
6.2.6. Germany 

6.2.6.1. Market size and forecast, by type, 2020-2027
6.2.6.2. Market size and forecast, by technology, 2020-2027
6.2.6.3. Market size and forecast, by end-user, 2020-2027
6.2.6.4. Comparative market share analysis, 2020 & 2027

6.2.7. UK

6.2.7.1. Market size and forecast, by type, 2020-2027
6.2.7.2. Market size and forecast, by technology, 2020-2027
6.2.7.3. Market size and forecast, by end-user, 2020-2027
6.2.7.4. Comparative market share analysis, 2020 & 2027

6.2.8. France

6.2.8.1. Market size and forecast, by type, 2020-2027
6.2.8.2. Market size and forecast, by technology, 2020-2027
6.2.8.3. Market size and forecast, by end-user, 2020-2027
6.2.8.4. Comparative market share analysis, 2020 & 2027

6.2.9. Spain

6.2.9.1. Market size and forecast, by type, 2020-2027
6.2.9.2. Market size and forecast, by technology, 2020-2027
6.2.9.3. Market size and forecast, by end-user, 2020-2027
6.2.9.4. Comparative market share analysis, 2020 & 2027

6.2.10. Italy 

6.2.10.1. Market size and forecast, by type, 2020-2027
6.2.10.2. Market size and forecast, by technology, 2020-2027
6.2.10.3. Market size and forecast, by end-user, 2020-2027
6.2.10.4. Comparative market share analysis, 2020 & 2027

6.2.11. Rest of Europe

6.2.11.1. Market size and forecast, by type, 2020-2027
6.2.11.2. Market size and forecast, by technology, 2020-2027
6.2.11.3. Market size and forecast, by end-user, 2020-2027
6.2.11.4. Comparative market share analysis, 2020 & 2027

6.3. Asia Pacific

6.3.1. Market size and forecast, by type, 2020-2027
6.3.2. Market size and forecast, by technology, 2020-2027
6.3.3. Market size and forecast, by end-user, 2020-2027
6.3.4. Market size and forecast, by country, 2020-2027
6.3.5. Comparative market share analysis, 2020 & 2027
6.3.6. China

6.3.6.1. Market size and forecast, by type, 2020-2027
6.3.6.2. Market size and forecast, by technology, 2020-2027
6.3.6.3. Market size and forecast, by end-user, 2020-2027
6.3.6.4. Comparative market share analysis, 2020 & 2027

6.3.7. India 

6.3.7.1. Market size and forecast, by type, 2020-2027
6.3.7.2. Market size and forecast, by technology, 2020-2027
6.3.7.3. Market size and forecast, by end-user, 2020-2027
6.3.7.4. Comparative market share analysis, 2020 & 2027

6.3.8. Australia 

6.3.8.1. Market size and forecast, by type, 2020-2027
6.3.8.2. Market size and forecast, by technology, 2020-2027
6.3.8.3. Market size and forecast, by end-user, 2020-2027
6.3.8.4. Comparative market share analysis, 2020 & 2027

6.3.9. Rest of Asia Pacific

6.3.9.1. Market size and forecast, by type, 2020-2027
6.3.9.2. Market size and forecast, by technology, 2020-2027
6.3.9.3. Market size and forecast, by end-user, 2020-2027
6.3.9.4. Comparative market share analysis, 2020 & 2027

6.4. LAMEA

6.4.1. Market size and forecast, by type, 2020-2027
6.4.2. Market size and forecast, by technology, 2020-2027
6.4.3. Market size and forecast, by end-user, 2020-2027
6.4.4. Market size and forecast, by country, 2020-2027
6.4.5. Comparative market share analysis, 2020 & 2027

6.4.6. Latin America  

6.4.6.1. Market size and forecast, by type, 2020-2027
6.4.6.2. Market size and forecast, by technology, 2020-2027
6.4.6.3. Market size and forecast, by end-user, 2020-2027
6.4.6.4. Comparative market share analysis, 2020 & 2027

6.4.7. Middle East 

6.4.7.1. Market size and forecast, by type, 2020-2027
6.4.7.2. Market size and forecast, by technology, 2020-2027
6.4.7.3. Market size and forecast, by end-user, 2020-2027
6.4.7.4. Comparative market share analysis, 2020 & 2027

6.4.8. Africa

6.4.8.1. Market size and forecast, by type, 2020-2027
6.4.8.2. Market size and forecast, by technology, 2020-2027
6.4.8.3. Market size and forecast, by end-user, 2020-2027
6.4.8.4. Comparative market share analysis, 2020 & 2027

7. Company Profiles

7.1. AptarGroup Inc.

7.1.1. Business overview
7.1.2. Financial performance
7.1.3. Product portfolio
7.1.4. Recent strategic moves & developments
7.1.5. SWOT analysis

7.2. Adherium

7.2.1. Business overview
7.2.2. Financial performance
7.2.3. Product portfolio
7.2.4. Recent strategic moves & developments
7.2.5. SWOT analysis

7.3. Proteus Digital Health

7.3.1. Business overview
7.3.2. Financial performance
7.3.3. Product portfolio
7.3.4. Recent strategic moves & developments
7.3.5. SWOT analysis

7.4. BD

7.4.1. Business overview
7.4.2. Financial performance
7.4.3. Product portfolio
7.4.4. Recent strategic moves & developments
7.4.5. SWOT analysis

7.5. F. Hoffmann-La Roche Ltd

7.5.1. Business overview
7.5.2. Financial performance
7.5.3. Product portfolio
7.5.4. Recent strategic moves & developments
7.5.5. SWOT analysis

7.6. propeller Health

7.6.1. Business overview
7.6.2. Financial performance
7.6.3. Product portfolio
7.6.4. Recent strategic moves & developments
7.6.5. SWOT analysis

7.7. Cohero Health, Inc.

7.7.1. Business overview
7.7.2. Financial performance
7.7.3. Product portfolio
7.7.4. Recent strategic moves & developments
7.7.5. SWOT analysis

7.8. Ypsomed AG

7.8.1. Business overview
7.8.2. Financial performance
7.8.3. Product portfolio
7.8.4. Recent strategic moves & developments
7.8.5. SWOT analysis

7.9. Syncro Technology Corp.

7.9.1. Business overview
7.9.2. Financial performance
7.9.3. Product portfolio
7.9.4. Recent strategic moves & developments
7.9.5. SWOT analysis

7.10. West Pharmaceutical Services

7.10.1. Business overview
7.10.2. Financial performance
7.10.3. Product portfolio
7.10.4. Recent strategic moves & developments
7.10.5. SWOT analysis

The connected drug delivery products are used to address patient’s issues related to disease management protocols, medications, and treatments. Connected drug delivery is one of the emerging solutions equipped with a sensor that facilitates connection and transfer of data to servers/applications via near field communication (NFC), Bluetooth, or cellular networks.

Factors Enhancing the Growth of the Industry

Increasing cases of chronic disorders such as diabetes, asthma, and COPD are the main attributors behind the growth of connected drug delivery technologies. A study conducted by researchers at Tongji Medical College and Huazhong University of Science and Technology, China asserts that the fatalities related to chronic lung diseases have been increased by almost 18%, from 3.3 million in 1990 to 3.9 million in 2017 worldwide. However, several companies operating in connected drug delivery technologies are implementing effective strategies to gain a prime position in the global industry and thus helping in reducing the death rates.

Recent Advances in the Industry

According to a report published by Research Dive , the leading players of connected drug delivery market include Propeller Health, Adherium, BD, West Pharmaceutical Services, F. Hoffmann-La Roche Ltd, Ypsomed AG, Syncro Technology Corp., AptarGroup Inc, Cohero Health, Inc., and Proteus Digital Health.

Unique and smart strategies are being developed by these market players to take the market to another height. The strategies include product innovation and launches, technology and product upgradation, mergers and acquisitions, and partnerships and collaborations.

Some of the recent updates of the market are mentioned below:

  1. As per a recent update, Propeller Health is cooperating with Novartis to co-package the Propeller digital health platform with recently approved Enerzair Breezhaler. Novartis has developed this product to treat uncontrolled asthma.
  2. Another news states, Adherium (NZ) Limited, one of the leading player of the market, has initiated a long term partnership with AstraZeneca, a multinational biopharmaceutical company based out of London. The mission behind this partnership is to develop a first-in-world commercial arrangement combining digital health technology with epic inhaler medications to provide better treatment to patients with respiratory conditions.
  3. LEO Pharma A/S and Portal Instruments has recently made an announcement regarding a global collaboration and license agreement to develop Portal’s innovative needle-free drug delivery system for use in combination with LEO Pharma’s portfolio of investigational and approved medicines.
    Portal needle-free system includes a re-usable, software-controlled handheld injection device and a proprietary, single-use, pre-filled cartridge. In this system, the medicine is injected through a pressurized liquid jet. This is a clinically-proven less painful system compared to a standard needle-based injection.
  4. Nemera’s Safe’n’Spray smart electronic concept device has achieved the acknowledgement as the “Best Innovation in Drug Delivery Device” at Pharmapack awards in February, 2020. 
  5. Headquartered in USA, AptarGroup, Inc. is a global manufacturer of consumer dispensing, active packaging and drug delivery solutions. Recently, this company has announced a collaboration with Sonmol, a leading Chinese digital respiratory therapeutics company. This collaboration aimed at developing a digital therapies and services platform especially for respiratory diseases.
  6. In November 2019, LOG pharma, another leading player in the healthcare sector, has announced the launch of a smart device, IoT-enabled ‘ActiveGuard’ connect. This innovative device is primarily developed to address the problem of lack of patient adherence to prescribed medications.
  7. January 2018, Aptar Group, a pioneer in drug delivery systems provider hold an exhibition at Pharmapack 2018. In this event, the organization exhibited its significant connected healthcare solutions with various patient-friendly features. 

With the COVID-19 outbreak, the global connected drug delivery market has experienced a massive progress. Some global leaders in the connected drug delivery devices market are coming forward with strategic initiatives to serve the society with their products and services during the catastrophic time. 

For instance, in January 2020, Aptar Pharma, a pioneer in drug delivery systems announced its partnership with Lupin to Launch ADHERO, India’s 1st connected drug delivery device for the COPD (chronic obstructive pulmonary disease) and asthma suffering patients. The device is Bluetooth enabled and improves the adherence to prescribed therapy along with track MDI (Metered-dose inhaler) usage of patients with chronic respiratory diseases.

In February 2020, BD (Becton, Dickinson and Company), a significant global medical technology company, made an announcement of the completion of a 50-subject human clinical trial by using ‘BD Libertas Wearable Injector’. 
Such brave and encouraging initiatives taken by the global market players have enhanced the growth of the connected drug delivery market during the pandemic.

Purchase Options

Inquire To Buy

Personalize this research

  • Triangulate with your own data
  • Request your format and definition
  • Get a deeper dive on a specific application, geography, customer or competitor
10% Off on Customization
Contact Us

Customers Also Viewed